Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
In this high incidence population, daily tenofovir–emtricitabine conferred even higher
protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness
would be less in a real-world setting. There was no evidence of an...